Article PDF first page preview

First page of Mind-Body Intervention in Chronic Lymphocytic Leukemia During the Watch-and-Wait Phase: Benefits Linked to Intervention Duration

Introduction: Mind-Body Interventions (MBI) are therapeutic practices that target the interactions between cognitive, emotional, and physiological systems to influence health outcomes. Previously, we demonstrated that MBI prolonged lymphocyte doubling time (LDT) and treatment-free survival (TFS) in treatment-naïve chronic lymphocytic leukemia (CLL) patients during the watch-and-wait phase. In this follow-up study, we investigated the long-term effects of MBI on TFS after the intervention ceased. Methods: 60 participants from the initial study (34 who received intervention vs. 26 controls) were followed for an additional period of 20 months. TFS was assessed from the end of the intervention to the initiation of CLL therapy or death, using Kaplan-Meier analysis and the log-rank test. Results: By the end of the follow-up, 9 participants who previously received MBI and 6 controls initiated CLL treatment. No significant difference in TFS was found between the groups (log-rank test p = 0.65). Conclusion: While MBI provided a clear advantage as long as it continued, our follow-up analysis suggests this effect diminishes after the intervention ends. Continuous or repeated MBI may be necessary for sustained improvements in TFS.

Journal Section:
Interdisciplinary Perspectives in Hematology
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.